Mustang Bio (NASDAQ:MBIO) Upgraded by Zacks Investment Research to Hold

Share on StockTwits

Mustang Bio (NASDAQ:MBIO) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Friday, Zacks.com reports.

According to Zacks, “Mustang Bio, Inc. a subsidiary of Fortress Biotech, Inc., is a clinical?stage biopharmaceutical company. It focused on the development and commercialization of novel cancer immunotherapy products designed to leverage the patient’s own immune system to eliminate cancer cells. Mustang Bio, Inc. is based in New York, United States. “

A number of other equities research analysts have also recently issued reports on the stock. ValuEngine raised shares of Mustang Bio from a “hold” rating to a “buy” rating in a research report on Thursday, February 27th. HC Wainwright reissued a “buy” rating and issued a $7.00 target price on shares of Mustang Bio in a research report on Tuesday, February 18th. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $7.00 target price on shares of Mustang Bio in a research report on Thursday, January 9th.

Shares of Mustang Bio stock opened at $2.70 on Friday. The firm has a 50-day moving average of $3.11 and a 200-day moving average of $3.37. The stock has a market cap of $98.16 million, a PE ratio of -2.08 and a beta of 2.23. Mustang Bio has a 52-week low of $1.78 and a 52-week high of $10.20. The company has a debt-to-equity ratio of 0.27, a quick ratio of 8.12 and a current ratio of 8.12.

Mustang Bio (NASDAQ:MBIO) last announced its earnings results on Monday, March 16th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.26) by ($0.16). Equities research analysts predict that Mustang Bio will post -1.19 earnings per share for the current fiscal year.

Institutional investors have recently made changes to their positions in the company. Ikarian Capital LLC acquired a new position in Mustang Bio in the fourth quarter valued at about $1,319,000. Parkman Healthcare Partners LLC acquired a new position in Mustang Bio in the fourth quarter valued at about $1,233,000. Oxford Asset Management LLP raised its stake in Mustang Bio by 415.9% in the fourth quarter. Oxford Asset Management LLP now owns 226,708 shares of the company’s stock valued at $925,000 after purchasing an additional 182,767 shares in the last quarter. State Street Corp raised its stake in Mustang Bio by 49.7% in the third quarter. State Street Corp now owns 477,694 shares of the company’s stock valued at $1,557,000 after purchasing an additional 158,696 shares in the last quarter. Finally, Renaissance Technologies LLC raised its stake in Mustang Bio by 9.2% in the fourth quarter. Renaissance Technologies LLC now owns 766,972 shares of the company’s stock valued at $3,129,000 after purchasing an additional 64,500 shares in the last quarter. 21.61% of the stock is owned by institutional investors.

Mustang Bio Company Profile

Mustang Bio, Inc, a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

See Also: What are momentum indicators and what do they show?

Get a free copy of the Zacks research report on Mustang Bio (MBIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Mustang Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mustang Bio and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Fuchs Petrolub  Given a €36.00 Price Target by Kepler Capital Markets Analysts
Fuchs Petrolub Given a €36.00 Price Target by Kepler Capital Markets Analysts
Independent Research Analysts Give freenet  a €17.00 Price Target
Independent Research Analysts Give freenet a €17.00 Price Target
Evonik Industries  Given a €19.00 Price Target by Kepler Capital Markets Analysts
Evonik Industries Given a €19.00 Price Target by Kepler Capital Markets Analysts
Independent Research Analysts Give Deutsche Telekom  a €15.50 Price Target
Independent Research Analysts Give Deutsche Telekom a €15.50 Price Target
Berenberg Bank Analysts Give Deutsche Bank  a €4.50 Price Target
Berenberg Bank Analysts Give Deutsche Bank a €4.50 Price Target
adidas  PT Set at €265.00 by Goldman Sachs Group
adidas PT Set at €265.00 by Goldman Sachs Group


© 2006-2020 Ticker Report